Results 51 to 60 of about 117,976 (202)

Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development

Journal of Diabetes Investigation, 2019
Today, glucagon‐like peptide‐1 (GLP‐1) receptor agonists are established glucose‐lowering drugs used in the management of type 2 diabetes. Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin ...
Bo Ahrén
doaj   +1 more source

Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]

, 2014
Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D., Milligan, Graeme, Ulven, Trond, Watterson, Kenneth R.   +3 more
core   +2 more sources

A single supplement of a standardised bilberry (Vaccinium myrtillus L.) extract (36 % wet weight anthocyanins) modifies glycaemic response in individuals with type 2 diabetes controlled by diet and lifestyle [PDF]

, 2013
Peer reviewedPublisher ...
Bestwick, Charles, Cruickshank, Morven, Hoggard, Nigel, Holst, Jens J, Horgan, Graham, Moar, Kim-Marie, Russell, Wendy   +6 more
core   +1 more source

The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas [PDF]

Diabetologia, 2007
Glucagon-like peptide-2 (GLP-2) is a gut hormone regulating intestinal growth and nutrient absorption. Recently, GLP-2 has been reported to stimulate glucagon secretion in healthy humans. We sought to clarify the mechanism and physiological significance of this endocrine effect.The expression of the GLP-2 receptor gene, Glpr2, and the localisation of ...
de Heer, J, Pedersen, J, Orskov, C, Holst, Jens Juul   +3 more
openaire   +3 more sources

First-in-class oral semaglutide: Overcoming barriers of incretinisation in the Indian context

Indian Journal of Endocrinology and Metabolism, 2022
Despite the availability of multiple therapeutic options and strategies, patients with type 2 diabetes mellitus (T2DM) the world over have inadequate glycaemic control and India is no exception.
Rajesh Rajput, Sujoy Ghosh, Samar Banerjee, Beena Bansal, Manoj Chawla, Abhay I Ahluwalia, Tejal Lathia, Ashok K Das   +7 more
doaj   +1 more source

c-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines [PDF]

, 2016
It is widely accepted that the c-Fos gene has a role in proliferation and differentiation of bone cells. ATP-induced c-Fos activation is relevant to bone homeostasis, because nucleotides that are present in the environment of bone cells can contribute to
A Gartland, A Liedert, A Trümper, AE Grigoriadis, BM Wice, C Kaebisch, C Meier, CJ Dixon, D Xie, DB Henriksen, DB Henriksen, DB Henriksen, DJ Drucker, E Velázquez, EL Pacheco-Pantoja, Elda Leonor Pacheco-Pantoja, IR Orriss, IR Orriss, J Kim, J Parker, James A. Gallagher, Jane P. Dillon, JE Koch, JV Zhang, KA Buckley, M-C Beauvieux, MC Bunck, MJ Hayton, Peter J. M. Wilson, RJ Bollag, S Sasaki-Hamada, S Sasaki-Hamada, S Susini, T Inhoff, T Tsuboi, WB Bowler, William D. Fraser   +36 more
core   +1 more source

Integrating the inputs that shape pancreatic islet hormone release. [PDF]

, 2019
The pancreatic islet is a complex mini organ composed of a variety of endocrine cells and their support cells, which together tightly control blood glucose homeostasis.
Huising, Mark O, Noguchi, Glyn M
core  

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]

, 2018
Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V., Goodwill, Adam, Green, Mark A., Hamilton, LaTonya, Hutchins, Gary D., Mather, Kieren J., Mathias, Carla, Patel, Niral A., Territo, Wendy, Tune, Johnathan D.   +9 more
core   +1 more source

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Journal of Pharmaceutical Policy and Practice
Background High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot
Michael J. DiStefano, Mouna Dardouri, Gina D. Moore, Joseph J. Saseen, Kavita V. Nair   +4 more
doaj   +1 more source

Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?

Journal of Diabetes Research, 2017
Background. The incretin effect is impaired in patients with type 2 diabetes. Aim. To assess the relation between the incretin hormone GLP-1 and the prediabetic subtypes: impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and the combined ...
Matthias Ploug Larsen, Signe Sørensen Torekov   +1 more
doaj   +1 more source